MedTrace Logo

Evaluation of AZD8154 Concentrations in Blood

NCT04480879 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-24

No results posted yet for this study

Summary

This study is intended to evaluate the systemic pharmacokinetic (PK) characteristics and the safety of AZD8154 following administration of the Monodose DPI formulation compared with the administration of the nebuliser suspension.

Conditions

Interventions

DRUG

AZD8154 nebuliser

Nebuliser suspension

DRUG

AZD8154 Monodose DPI presented in capsules

AZD8154 Monodose DPI formulation delivered dose

DRUG

AZD8154 Placebo Monodose DPI presented in capsules

The dose correspond to AZD8154 Monodose DPI formulation

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2020-09-02
Completion
2020-09-02

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480879 on ClinicalTrials.gov